Antistoffer hos patienter med kronisk inflammatorisk demyeliniserende polyneuropati

Translated title of the contribution: Antibodies in patients with chronic inflammatory demyelinating polyneuropathy

Abdullahi Ahmed Momamed, Thomas Krøigård, Thomas Agerbo Gaist, Lars Kjøbsted Markvardsen, Søren Hein Sindrup, Henning Andersen, Morten Blaabjerg

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

Recent studies have identified specific immunoglobulin (Ig) G4 antibodies against the paranodal proteins neurofascin 155 and contactin 1 in subgroups of patients with chronic inflammatory demyelinating polyneuropathy (CIDP). These patients present with distinct clinical phenotypes and poor response to first-line therapy with intravenous Ig. Detection of these antibodies in patients with CIDP has diagnostic, prognostic, and therapeutic implications. This review summarises the current knowledge on clinical characteristics, pathogenesis and treatment of these patients.
Original languageDanish
Article numberV08180526
JournalUgeskrift for Laeger
Volume181
Issue number16
ISSN0041-5782
Publication statusPublished - Aug 2019

Fingerprint

Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Intravenous Immunoglobulins
Proteins

Cite this

Momamed, Abdullahi Ahmed ; Krøigård, Thomas ; Agerbo Gaist, Thomas ; Markvardsen, Lars Kjøbsted ; Sindrup, Søren Hein ; Andersen, Henning ; Blaabjerg, Morten. / Antistoffer hos patienter med kronisk inflammatorisk demyeliniserende polyneuropati. In: Ugeskrift for Laeger. 2019 ; Vol. 181, No. 16.
@article{712d0f7ffcb24912bc4b22e7ba45199e,
title = "Antistoffer hos patienter med kronisk inflammatorisk demyeliniserende polyneuropati",
abstract = "Recent studies have identified specific immunoglobulin (Ig) G4 antibodies against the paranodal proteins neurofascin 155 and contactin 1 in subgroups of patients with chronic inflammatory demyelinating polyneuropathy (CIDP). These patients present with distinct clinical phenotypes and poor response to first-line therapy with intravenous Ig. Detection of these antibodies in patients with CIDP has diagnostic, prognostic, and therapeutic implications. This review summarises the current knowledge on clinical characteristics, pathogenesis and treatment of these patients.",
author = "Momamed, {Abdullahi Ahmed} and Thomas Kr{\o}ig{\aa}rd and {Agerbo Gaist}, Thomas and Markvardsen, {Lars Kj{\o}bsted} and Sindrup, {S{\o}ren Hein} and Henning Andersen and Morten Blaabjerg",
year = "2019",
month = "8",
language = "Dansk",
volume = "181",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "16",

}

Momamed, AA, Krøigård, T, Agerbo Gaist, T, Markvardsen, LK, Sindrup, SH, Andersen, H & Blaabjerg, M 2019, 'Antistoffer hos patienter med kronisk inflammatorisk demyeliniserende polyneuropati', Ugeskrift for Laeger, vol. 181, no. 16, V08180526.

Antistoffer hos patienter med kronisk inflammatorisk demyeliniserende polyneuropati. / Momamed, Abdullahi Ahmed; Krøigård, Thomas; Agerbo Gaist, Thomas; Markvardsen, Lars Kjøbsted; Sindrup, Søren Hein; Andersen, Henning; Blaabjerg, Morten.

In: Ugeskrift for Laeger, Vol. 181, No. 16, V08180526, 08.2019.

Research output: Contribution to journalJournal articleResearchpeer-review

TY - JOUR

T1 - Antistoffer hos patienter med kronisk inflammatorisk demyeliniserende polyneuropati

AU - Momamed, Abdullahi Ahmed

AU - Krøigård, Thomas

AU - Agerbo Gaist, Thomas

AU - Markvardsen, Lars Kjøbsted

AU - Sindrup, Søren Hein

AU - Andersen, Henning

AU - Blaabjerg, Morten

PY - 2019/8

Y1 - 2019/8

N2 - Recent studies have identified specific immunoglobulin (Ig) G4 antibodies against the paranodal proteins neurofascin 155 and contactin 1 in subgroups of patients with chronic inflammatory demyelinating polyneuropathy (CIDP). These patients present with distinct clinical phenotypes and poor response to first-line therapy with intravenous Ig. Detection of these antibodies in patients with CIDP has diagnostic, prognostic, and therapeutic implications. This review summarises the current knowledge on clinical characteristics, pathogenesis and treatment of these patients.

AB - Recent studies have identified specific immunoglobulin (Ig) G4 antibodies against the paranodal proteins neurofascin 155 and contactin 1 in subgroups of patients with chronic inflammatory demyelinating polyneuropathy (CIDP). These patients present with distinct clinical phenotypes and poor response to first-line therapy with intravenous Ig. Detection of these antibodies in patients with CIDP has diagnostic, prognostic, and therapeutic implications. This review summarises the current knowledge on clinical characteristics, pathogenesis and treatment of these patients.

M3 - Tidsskriftartikel

VL - 181

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 16

M1 - V08180526

ER -

Momamed AA, Krøigård T, Agerbo Gaist T, Markvardsen LK, Sindrup SH, Andersen H et al. Antistoffer hos patienter med kronisk inflammatorisk demyeliniserende polyneuropati. Ugeskrift for Laeger. 2019 Aug;181(16). V08180526.